Immutep (ASX:IMM) has dosed the first patient in its TACTI-004 phase 3 trial evaluating a potential combination therapy for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The trial is assessing Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with NYSE-listed Merck's Keytruda anti-PD-1 therapy and chemotherapy as first-line treatment for patients with advanced or metastatic non-small cell lung cancer, per the filing.
The study's dual primary endpoints are progression-free survival and overall survival. Results will support a potential marketing approval application.
The global trial will enroll 756 patients at more than 150 clinical sites in over 25 countries, the filing stated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。